High-dose fluconazole therapy in Intensive Care Unit

Minerva Anestesiologica

Volumn 69, Issue 3, 2003, Pages 145-157

  De Bellis, P ^a,b   Bonfiglio, M ^a   Gerbi, G ^a   Bacigalupo, P ^a   Buscaglia, G ^a   Guido, P ^a   Massobrio, B ^a  

^a GALLIERA HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Antifungal agents, therapeutic use; Fluconazole; Intensive care unit; Mycoses, drug therapy; Mycoses, prevention and control

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN; FLUCONAZOLE; ANTIFUNGAL AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CANDIDIASIS; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; FUNGAL COLONIZATION; HUMAN; INTENSIVE CARE UNIT; LABORATORY; MEDICAL INSTRUMENTATION; MORBIDITY; MORTALITY; MYCOSIS; PARENTERAL NUTRITION; RISK FACTOR; TREATMENT OUTCOME; URINE CULTURE; ADULT; AGED; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; URINE;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDIASIS; FEMALE; FLUCONAZOLE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES;

EID: 0141991832     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Beck-Sague C, Javis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990, NNISS. J Infect Dis 1993;167:1247-51.
2. Vincent JL, Anaissie E, Bruning H, Demajo W, Ebiary MEL, Haber J et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998;24:206-16.
3. Kramer KM, Skaar DJ, Ackerman BH. The fluconazole era: management of hematogenously disseminated candidiasis in the nonneutropenic patients. Pharmacotherapy 1997;17:538-48.
4. Garbino J, Pittet D. Candida infections in the ICU CL. Intensive Care 1997, 8:187-200.
5. Rex JH. Editorial response: catheters and candidemia. Clin Infect Dis 1996;22:467-70.
6. Lawrence ND, Liberati DM, Diglio CA, Duchavsky SA, Brown WJ. Synergistic effects of Candida and E. Coli on gut barrier function. J Trauma 1999;47:1045-51.
7. Rex JH, Pfaller MA, Galgiani JN. Development of interpretative breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro- in vivo correlation data for fluconazole, intraconazole and Candida infections. Clin Infect Dis 1997;24:235-47.
8. Rangel-Frausto MS, Wiblin T, Blumberg H. National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in 7 surgical intensive care units. Clin Infect Dis 1999;29:253-8.
9. British Society Antimicrobial Chemotherapy. Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 1994;20:522-8.
10. Pittet D, Anaissie E, Solomkin JS. When to start antifungal therapy in the non-neutropenic critically ill? Yearbook of Intensive Care and Emergency Medicine. Saint Louis, MO: Mosby; 1996.p.567-77.
11. Voss A, de Paw BE. High-dose fluconazole therapy in patients with severe fungal infection. Eur J Microbiol Infect Dis 1999;18:165-74.
12. Patterson TF. Role of newer azoles in surgical patients. J Chemiother 1999;11:504-12.
13. Nolla-Salas JC, Leon J M, Torres Rodriguez E, Martin A, Sitges-Serra C. Treatment of candidemia in critically ill surgical patients with intravenous fluconazole. Clin Infect Dis 1992;14:952-4.
14. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. For the Sentry participant group International Surveillance of Bloodstream Infections due to Candida Species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for SENTRY Program. J Microbiol 1998;36:1886-9.
15. Burnie JP, Odds FC, Lee W, Webster C, Williams JD. Outbreak of systemic Candida albicans in intensive Care Unit caused by cross infection. Br Med J 1985;290:746-8.
16. Brooks RG. Prospective Study of Candida endophtalmitis in hospitalized patients with candidemia. Arch Intern Med 1989;149:2226-8.
17. A. Voss, Le Noble L, Verdujn Lunel FM, Foudraine NA, Meis JFGM. Candidemia in Intensive care Unit patients risk factors for mortality. Infection 1997;25:8-11.
18. Fraser V, Jones M, Dunkel, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital. Epidemiology, risk factors and predictors of mortality. Clin Infect Dis 1992;15:414-21.
19. Voss A, Hollis RG, Pfallern MA, Wenzel RP, Doebbeling BN. Investigation of sequence of colonization and candidemia in non neutropenic patients. J Clin Microbiol 1994;32:975-80.
20. Anaissie EJ, Darouiche RO, Abi-Said D, Uzum O, Mera J, Gently LO et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus anfoB and review of literature. Clin Infect Dis 1996;23:964-72.
21. Anaissie EJ, Vartivarian SE, Abisaid D, Uzun O, Pinczowski H, Kontojiannis DP et al. Fluconazole versus anfoB in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
22. Lelarge P, Mariot J. Systemic candidiasis. Ann Fr Anesth Reanim 1992;11:558-75.
23. Demajo WA, Guimond JG, Rotstein C, Tweeddale M and the Canadian Candidemia Advisory group. Guidelines for the management of nosocomial Candida infections in non-neutropenic intensive care patients. Can J Infect Dis 1997;8:38-88.